Antibody response to influenza immunization in coronary artery disease patients: a controlled trial.
Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.
Keshtkar-Jahromi
Maryam
M
Clinical Research & Development Center, Shahid Modarres Medical Center, Shahid Beheshti University (MC), Tehran, Iran. maryam keshtkar@yahoo.com
Vakili
Hossein
H
Rahnavardi
Mohammad
M
Gholamin
Sharareh
S
Razavi
Seyed-Mostafa
SM
Eskandari
Ali
A
Sadeghi
Roxana
R
Vatan-Pour
Hossein
H
Keshtkar-Jahromi
Marzieh
M
Haghighat
Babak
B
Ghaffaripour
Mohammad
M
Mokhtari-Azad
Talat
T
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000917:Antibody Formation / Q000276:immunology*; D003324:Coronary Artery Disease / Q000276:immunology* / Q000821:virology; D005260:Female; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016896:Treatment Outcome
D000914:Antibodies, Viral; D007252:Influenza Vaccines